Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS002 in Hypercholesterolemia (Ib/II)
CTR20190162Phase 2Completed
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Jan 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ongericimab in hypercholesterolemia, combined dyslipidaemia, familial hypercholesterolemia (FH), atherosclerotic disease, sponsored by Shanghai Junshi Biosciences Co., Ltd.. Started Jan 2019; status: completed.
02
Drugs
ongericimab
03
Conditions
hypercholesterolemiacombined dyslipidaemiafamilial hypercholesterolemia (FH)atherosclerotic disease
Beyond the preview
Go deeper on CTR20190162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190162.